Q&A Session with Biosimilar Roundtable Panelists – Dr Richard Easton

RLE profile shot

Dr. Richard Easton

biopharmaspec-logo

Technical Director for Structural Analysis
BioPharmaSpec

Dr. Richard Easton is the Technical Director for Structural Analysis at BioPharmaSpec, an independent analytical CRO with labs in the UK & US. He has over 20 years’ experience in glycoprotein structural characterization using mass spectrometry and is well acquainted with the various regulatory requirements for biopharmaceutical development.

FG: Richard, why is it so important to perform comparative glycosylation analyses with Biosimilars? Do we really expect the structures to be the same when the manufacture is not? What do we do when differences are detected in the glycans and how can we integrate results from these analyses with data from functional analyses?

FG: What then are the main techniques you would utilize when carrying out comparative glycan analyses… and do you have a favorite?!

FG: Every few years in the field of analytical instrumentation there is a breakthrough new technique/ instrument development which revolutionizes the study of glycoprotein molecules. What would you say were the most significant developments during your career?